To explore potential determinants of engraftment, we evaluated MF disease characteristics including primary vs secondary MF, driver mutations in JAK2, CALR and MPL, prognostic risk group, splenomegaly and BM fibrosis as well as ruxolitinib therapy before HCT. The gene discussed is JAK2; the disease is Splenomegaly.